Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.

Abstract

Hepatocellular carcinoma (HCC) is the second or third leading cause of cancer mortality worldwide (depending on which statistics are used), yet there is no effective treatment. Currently, there are nine FDA-approved drugs for HCC, five monoclonal antibodies and four tyrosine kinase inhibitors. Ornithine aminotransferase (OAT) has been validated as a target in preclinical studies, which demonstrates that it is a potential target to treat HCC. Currently, there are no OAT inactivators in clinical trials for HCC. This Innovation describes evidence to support inhibition of OAT as a novel approach for HCC tumor growth inhibition. After the mechanism of OAT is discussed, the origins of our involvement in OAT inactivation, based on our previous work on mechanism-based inactivation of GABA-AT, are described. Once it was demonstrated that OAT inactivation does lead to HCC tumor growth inhibition, new selective OAT inactivators were designed and their inactivation mechanisms were elucidated. A summary of these mechanistic studies is presented. Inactivators of OAT provide the potential for treatment of HCC, targeting the Wnt/β-catenin pathway.

• Authors: Richard B Silverman
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 13 Issue 1 Pg. 38-49 (Jan 13 2022) ISSN: 1948-5875 [Print] United States
• PMID: 35059122 (Publication Type: Journal Article)
• Copyright: © 2021 American Chemical Society.